Metabolic — approved in some markets
Tirzepatide 5 mg
A dual GIP/GLP-1 receptor agonist approved in several markets as a prescription medicine. Only registered, prescribed product from licensed channels should ever be considered.
What it is
Tirzepatide is a dual GIP and GLP-1 receptor agonist registered as a prescription medicine in a number of jurisdictions for defined indications.
Mechanism being studied
Agonism at GIP and GLP-1 receptors influences insulin secretion, gastric emptying and appetite regulation.
Human evidence
Large randomised controlled trials underpin its approved indications. Evidence applies to the registered product used under prescription, not to unregistered copies.
Safety considerations
Prescription-only where registered, with documented contraindications, warnings and adverse effects requiring clinical assessment and monitoring. Unregistered or compounded copies are a recognised public-health risk and have been the subject of regulator warnings. Safety information for this compound is incomplete outside of controlled settings. Reported considerations in the literature include injection-site reactions, unknown long-term effects, product-quality and sterility risks with unregistered preparations, and unpredictable interactions with existing medicines or conditions. Any consideration of use belongs with a registered healthcare professional who can assess the individual clinical picture.
Regulatory status
Approved medicine in several markets, prescription-only. Confirm South African registration status with SAHPRA. Only licensed pharmacy channels may supply registered product.
Certificate of analysis
Third-party analytical documentation for this compound is published for transparency and professional review. It confirms identity and purity of tested material only, and is not a marketing authorisation, a registration, or a recommendation for use.
View certificate (PDF)Key references
- Regulator-approved product information where registered.
- Published phase 3 randomised controlled trials.
- SAHPRA — warnings on unregistered GLP-1-type products.
References are provided as reading directions for professionals. They do not constitute endorsement of any use.
Information only — availability subject to applicable law, prescription/authorisation, and licensed healthcare/pharmacy channels. Nothing on this page is an offer to sell, and no dosing or self-administration guidance is provided.
South Africa — compliance notice
SAHPRA has publicly warned about unregistered peptide products being marketed to the South African public. In general, products intended to diagnose, treat, or otherwise alter bodily functions require registration or authorisation before they may lawfully be sold. ELLIVON BIOSCIENCES publishes reference information only and directs all clinical questions to registered healthcare professionals and licensed pharmacy channels.